Forbion IV Management B.V.
SEC CIK 2005384 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | 10% | 10.76M | — | $10.19M | 3 | 2024-12-12 | 2024-12-20 |
Most active insiders at NAMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| 2 | Kooij Louise Frederika | CAO | — | $16.75M |
| 3 | Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| 4 | Somaiya Mayur Ian | CFO | — | $3.43M |
| 5 | LANGE LOUIS G | Dir | — | $2.19M |
| 6 | Smither John W | Dir | — | $40.5K |
| 7 | Gunning Robert William | VP, Ctrl | — | — |
| 8 | van der Kamp Hilde Johanna | Dir | — | — |
| 9 | McKenna Mark C. | Dir | — | — |
| 10 | Gulfo Adele M. | Dir | — | — |
Forbion IV Management B.V. made no open-market trades at NAMS in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2024-12-26 | 2024-12-20+ | NAMS | NewAmsterdam Pharma Co N.V. | Forbion IV Management B.V. | 10% | S - Sale | $25.58 | -91.1K | 10.76M | -0.8% | -$2.33M |
| MTI | 2024-12-18 | 2024-12-16+ | NAMS | NewAmsterdam Pharma Co N.V. | Forbion IV Management B.V. | 10% | S - Sale | $25.95 | -115.5K | 11.12M | -1% | -$3.00M |
| MTI | 2024-12-16 | 2024-12-12+ | NAMS | NewAmsterdam Pharma Co N.V. | Forbion IV Management B.V. | 10% | S - Sale | $25.34 | -191.8K | 11.18M | -2% | -$4.86M |
Purchase Sale Sale after option exercise All abbreviations